Active Ingredient History
Natural killer cells, also known as NK cells or large granular lymphocytes (LGL), are a type of cytotoxic lymphocyte critical to the innate immune system that belong to the rapidly expanding family of known innate lymphoid cells (ILC) and represent 5–20% of all circulating lymphocytes in humans. The role of NK cells is analogous to that of cytotoxic T cells in the vertebrate adaptive immune response. NK cells provide rapid responses to virus-infected cell and other intracellular pathogens acting at around 3 days after infection, and respond to tumor formation. Typically, immune cells detect the antigen presented on major histocompatibility complex (MHC) on infected cell surfaces, triggering cytokine release, causing the death of the infected cell by lysis or apoptosis. NK cells are unique, however, as they have the ability to recognize and kill stressed cells in the absence of antibodies and MHC, allowing for a much faster immune reaction. They were named "natural killers" because of the notion that they do not require activation to kill cells that are missing "self" markers of MHC class 1. This role is especially important because harmful cells that are missing MHC I markers cannot be detected and destroyed by other immune cells, such as T lymphocyte cells. Wikipedia
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Aged (Phase 1/Phase 2)
Antigens, CD19 (Phase 1/Phase 2)
Biliary Tract Neoplasms (Phase 1/Phase 2)
Bone Marrow Cells (Phase 1)
Brain Neoplasms (Phase 1/Phase 2)
Breast Neoplasms (Phase 2)
Carcinoma, Hepatocellular (Phase 2/Phase 3)
Carcinoma, Merkel Cell (Phase 1)
Carcinoma, Mucoepidermoid (Phase 1)
Carcinoma, Non-Small-Cell Lung (Phase 2)
Carcinoma, Renal Cell (Phase 1)
Carcinoma, Squamous Cell (Phase 1)
Carcinoma, Transitional Cell (Phase 1)
Colonic Neoplasms (Phase 1)
Colorectal Neoplasms (Phase 1/Phase 2)
COVID-19 (Phase 1/Phase 2)
Fallopian Tube Neoplasms (Phase 2)
Glioblastoma (Phase 1)
Gliosarcoma (Phase 1)
Graft vs Host Disease (Phase 2)
Hamartoma (Phase 2)
Head and Neck Neoplasms (Phase 1)
Hematologic Neoplasms (Early Phase 1)
Hematopoietic Stem Cell Transplantation (Phase 1/Phase 2)
HIV (Phase 1)
HIV Infections (Phase 1)
Hodgkin Disease (Phase 2)
Immune System Diseases (Phase 1)
Intestinal Neoplasms (Phase 1)
Kidney Neoplasms (Phase 2)
Leukemia (Phase 2)
Leukemia, Biphenotypic, Acute (Phase 2)
Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)
Leukemia, Myeloid (Phase 2)
Leukemia, Myeloid, Acute (Phase 2)
Leukemia, Myeloid, Chronic-Phase (Phase 2)
Leukemia, Myelomonocytic, Chronic (Phase 2)
Leukemia, Myelomonocytic, Juvenile (Phase 2)
Leukemia, Plasma Cell (Phase 1/Phase 2)
Liver Neoplasms (Phase 2/Phase 3)
Living Donors (Phase 1/Phase 2)
Lung Neoplasms (Phase 1)
Lymphoma (Phase 2)
Lymphoma, B-Cell (Phase 2)
Lymphoma, Follicular (Phase 2)
Lymphoma, Large B-Cell, Diffuse (Phase 3)
Lymphoma, Large-Cell, Immunoblastic (Phase 2)
Lymphoma, Mantle-Cell (Phase 2)
Lymphoma, Non-Hodgkin (Phase 2)
Lymphoma, Primary Cutaneous Anaplastic Large Cell (Phase 1/Phase 2)
Lymphoma, T-Cell (Phase 1)
Lymphoproliferative Disorders (Phase 1/Phase 2)
Melanoma (Phase 2)
Mesothelioma (Phase 1)
Microsatellite Instability (Phase 1)
Multiple Myeloma (Phase 2)
Myelodysplastic Syndromes (Phase 2)
Myeloproliferative Disorders (Phase 2)
Nasopharyngeal Carcinoma (Phase 1/Phase 2)
Nasopharyngeal Neoplasms (Phase 1/Phase 2)
Neoplasm Metastasis (Phase 1)
Neoplasms (Phase 2)
Neuroblastoma (Phase 2)
Organ Transplantation (Phase 1)
Osteosarcoma (Phase 2)
Ovarian Neoplasms (Phase 2)
Pancreatic Neoplasms (Phase 1/Phase 2)
Rhabdomyosarcoma (Phase 2)
Sarcoma (Phase 1)
Sarcoma, Ewing (Phase 2)
Sarcoma, Myeloid (Phase 2)
Small Cell Lung Carcinoma (Phase 1)
Squamous Cell Carcinoma of Head and Neck (Phase 1/Phase 2)
Stem Cell Transplantation (Phase 1)
Stomach Neoplasms (Phase 1/Phase 2)
Tongue Neoplasms (Phase 1/Phase 2)
Uterine Cervical Neoplasms (Phase 1)
Waldenstrom Macroglobulinemia (Phase 1/Phase 2)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
